GTP cyclohydrolase I gene polymorphisms are associated with endothelial dysfunction and oxidative stress in patients with type 2 diabetes mellitus by Wołkow, Paweł et al.
GTP Cyclohydrolase I Gene Polymorphisms Are
Associated with Endothelial Dysfunction and Oxidative
Stress in Patients with Type 2 Diabetes Mellitus
Pawel P. Wolkow1,2, Wladyslaw Kosiniak-Kamysz3, Grzegorz Osmenda3, Grzegorz Wilk3,
Beata Bujak-Gizycka1,2, Adam Ignacak3, Mihir Kanitkar4, Malgorzata Walus-Miarka5, David G. Harrison4,
Ryszard Korbut2, Maciej T. Malecki5,6, Tomasz J. Guzik3,7*
1 Centre for Medical Genomics OMICRON, Jagiellonian University Medical College, Krakow, Poland, 2 Department of Pharmacology, Jagiellonian University Medical
College, Krakow, Poland, 3 Department of Internal and Agricultural Medicine, Jagiellonian University Medical College, Krakow, Poland, 4 Department of Clinical
Pharmacology, Vanderbilt University, Nashville, TN, United States of America, 5 Department of Metabolic Diseases, Jagiellonian University Medical College, Krakow,
Poland, 6 University Hospital, Krakow, Poland, 7 Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom
Abstract
Background: The genetic background of atherosclerosis in type 2 diabetes mellitus (T2DM) is complex and poorly
understood. Studying genetic components of intermediate phenotypes, such as endothelial dysfunction and oxidative
stress, may aid in identifying novel genetic components for atherosclerosis in diabetic patients.
Methods: Five polymorphisms forming two haplotype blocks within the GTP cyclohydrolase 1 gene, encoding a rate
limiting enzyme in tetrahydrobiopterin synthesis, were studied in the context of flow and nitroglycerin mediated dilation
(FMD and NMD), intima-media thickness (IMT), and plasma concentrations of von Willebrand factor (vWF) and
malondialdehyde (MDA).
Results: Rs841 was associated with FMD (p = 0.01), while polymorphisms Rs10483639, Rs841, Rs3783641 (which form a
single haplotype) were associated with both MDA (p = 0.012, p = 0.0015 and p = 0.003, respectively) and vWF concentrations
(p = 0.016, p = 0.03 and p = 0.045, respectively). In addition, polymorphism Rs8007267 was also associated with MDA
(p = 0.006). Haplotype analysis confirmed the association of both haplotypes with studied variables.
Conclusions: Genetic variation of the GCH1 gene is associated with endothelial dysfunction and oxidative stress in T2DM
patients.
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Introduction
Atherosclerosis and its clinical manifestations, such as myocar-
dial infarction and stroke, are the major causes of mortality in type
2 diabetes mellitus (T2DM) patients [1]. While major clinical and
biochemical risk factors are well known, several large randomized
clinical trials show ineffectiveness of intensive therapies in the
prevention of cardiovascular mortality in T2DM [2–4], suggesting
that not all therapeutic options have already been exploited. This
may be related to the complexity of the pathogenesis of
atherosclerosis, which is initiated and modified by numerous
genetic and environmental risk factors, many of which remain
unknown. Use of quantitative phenotypes, rather than dichoto-
mized presence of atherosclerosis or its clinical complications as
outcome variables, may increase the power to detect significant
genetic associations. In addition, intermediate quantitative phe-
notypes are usually associated with a single predominant
pathomechanism of atherosclerosis [5]. Thus, studies involving
such phenotypes are less prone to confounding by concomitant
factors [6]. The most important mechanisms of atherosclerosis
include lipid accumulation in the arterial wall [7], endothelial
dysfunction [8], imbalance in redox homeostasis [9] and chronic
inflammation [10]. While all of these mechanisms are important,
endothelial dysfunction seems to precede the development of
atherosclerotic plaque both locally [11] and systemically [12].
More importantly, endothelial dysfunction in human vessels from
diabetic subjects is primarily caused by increased oxidative stress,
which results primarily from the uncoupling of endothelial nitric
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oxide synthase (eNOS) [13]. In T2DM patients, uncoupled eNOS
contributes to net superoxide excess, rather than producing
protective nitric oxide (NO). This phenomenon is caused by the
loss of bioavailability of the eNOS co-factor - tetrahydrobiopterin
(BH4) and can be reversed by BH4 supplementation [13]. The
mechanism for decreased bioavailability of BH4 in T2DM is not
known. Several recent studies have shown that BH4 levels may be
modified by genetic variability of the GTP-cyclohydrolase 1
(GCH1) gene located on chromosome 14 in humans and encoding
a rate limiting enzyme in the complex process of tetrahydrobiop-
terin synthesis [14–16]. In the present study, we searched for the
association between the polymorphisms within the GCH1 gene
and selected intermediate, quantitative phenotypes related to
atherosclerosis in T2DM patients. These included endothelial
dysfunction (flow mediated dilation – FMD) and its biochemical
parameter (von Willebrand factor – vWF), measures of oxidative
stress (malondialdehyde levels – MDA), and subclinical athero-
sclerosis (intima-media thickness – IMT).
Materials and Methods
Study population
The study population consisted of 182 consecutive patients
diagnosed with T2DM and followed up in an outpatient setting at
the Department of Metabolic Diseases, University Hospital,
Krakow, Poland. During patient recruitment, the WHO defini-
tions and criteria of diabetes diagnosis were used [17]. All patients
were white Caucasians and inhabitants of southeastern Poland.
Upon examination, demographic data and information about the
course of their disease, family history, past and current treatments
and lifestyle habits were obtained. Only patients with clinical
diagnosis of T2DM and no insulin therapy, within the first year of
initial diagnosis, were included in this study. Blood for DNA
isolation and biochemical measurements, including MDA and
vWF plasma concentrations, was obtained by antecubital
venipuncture. Vasodilation and IMT were measured ultrasono-
graphically with an 8 MHz probe by a single researcher, blinded
to other data. Diagnosis of diabetic complications and biochemical
measurements were performed as previously described [17]. The
study was approved by the Bioethics Committee of the
Jagiellonian University. All patients provided informed consent.
Assessment of endothelial function
Endothelial function was assessed by flow mediated dilation
(FMD) measurement as described and validated by our laboratory
before [17,18]. Measurements were performed with the Toshiba
Xario Diagnostic Ultrasound System and an 8MHz linear
transducer. Briefly, measurements were recorded before 5 min-
ute-long brachial artery occlusion and then subsequently 1, 2 and
5 minutes after cuff deflation. Measurements during diastole were
recorded and maximal dilation (usually detected within ca. 60–
120 sec) was analyzed and reported. Maximal nitroglycerine
mediated dilation (NMD) was measured to study non-endothelium
dependent vasodilations. vWF concentration in plasma was
analyzed using a commercial ELISA kit from DAKO (Glostrup,
Denmark).
Measurement of IMT
Measurement of IMT was performed as previously described
[17,18] at 12 different points along the right and left common
carotid artery. Mean (IMTmean) and maximal IMT (IMTmax)
were calculated.
MDA determination
MDA in plasma was determined using liquid chromatography
with mass detection (HPLC/MS, LCQ Finnigan Matt). These
tests were performed at the Department of Pharmacology JUMC
by a modified method described by Sim et al. [19]. Plasma samples
were incubated with NaOH to liberate bound MDA and
perchloric acid to precipitate proteins. The supernatant was then
subjected to extraction twice with n-hexane. The separated
organic phase was analyzed by HPLC/MS.
Genotyping
Polymorphisms in the GCH1 gene were selected for genotyping
based on the existing literature [20,21]. The GCH1 gene spans
slightly over 60 kb on human chromosome 14 (physical location
54,378,474–54,439,292 on March 2006 build of human genome
according to UCSC genome browser). Linkage disequilibrium
(LD) in a European (Tuscany, Italy) and European descent (Utah,
USA) populations (CEU + TSI) from HapMap data [22] is shown
in Figure 1A. These populations combined are probably the best
available approximation of LD extent for White Caucasians, such
as a Polish population from Central Europe. Data show the
existence of two haplotype blocks of very tight LD, extending
beyond the gene boundaries. The boundary between these two
blocks is localized in the second intron, dividing the gene into two
thirds in the 59-end block and one third in the 39-end block.
Therefore, the polymorphisms for this association study were
selected from both haplotype blocks (Figure 1B). DNA was
isolated from peripheral blood leukocytes using a guanidinium
thiocyanate method (DNAzol, Life Technologies).
Polymorphisms rs10483639, rs841, rs3783641, rs10137071,
and rs8007267 were determined using commercially available kits
ABI TaqMan SNP Genotyping pre-designed assays (Applied
Biosystems, USA). End-point fluorescence was determined using
Applied Biosystems 7900HT Fast Real-Time PCR System
(Applied Biosystems, USA).
Statistical analysis
Data for statistical analysis were analyzed with SAS ver. 9.3
(Cary, USA). Deviations of genotype frequencies of studied
polymorphisms from Hardy-Weinberg equilibrium were tested
using a modified Chi-square test, implemented in the SAS
Genetics module. An extent of LD between the studied
polymorphisms was calculated and presented graphically with
Haploview ver. 4.1. Patients with different genotypes were
compared for differences in continuous variables using the
Wilcoxon test and in categorical variables using Chi-square or
Fisher’s exact test. To compare the effect of polymorphisms and
haplotype blocks on quantitative outcome variables, we used
PLINK ver. 1.06 with association tests based on Wald statistic.
Univariate tests of association were used for individual polymor-
phisms and haplotype blocks, multivariate tests for combinations
of polymorphisms and clinical variables. The following clinical
variables, potential confounders of association between genetic
factors and outcome variables, were tested: age and sex of patients,
characteristics of T2DM, risk factors of atherosclerosis and
medication used. P values of less than 0.05 were considered
statistically significant.
Results
Study population
Clinical characteristics of patients are summarized in Table 1.
These data include demographic characteristics (sex and age),
major risk factors for atherosclerosis, current therapies, history of
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diabetes and its complications, cardiovascular diseases, lipid
profile, and outcome phenotypes (FMD, NMD, vWF, and MDA).
LD in GCH1 gene in T2DM patients in Poland
The physical location of 5 genotyped polymorphisms on
chromosome 14 is described in Figure 1B. Linkage analysis of
genotyping data obtained in our study population revealed the
existence of 2 haplotype blocks, similar to the results obtained
using analysis of HapMap data (Figure 1A–C). Polymorphisms
rs10483639, rs841, and rs3783641 belong to the first haplotype
block while polymorphisms rs10137071 and rs8007267 belong to
the second haplotype block.
GCH1 genetic polymorphisms and vascular outcome
variables
We next studied the associations between each of the 5
genotyped SNPs, as well as each of the 2 haplotype blocks formed
by these SNPs, with outcome variables (Table 2). Polymorphism
rs841 was associated with endothelial function measured as
maximal FMD (Figure 2A), while no association was found with
control NMD (Figure 2B). Three polymorphisms belonging to the
same haplotype block (rs10483639, rs841, and rs3783641) were
associated with vWF concentration, a plasma biomarker of
endothelial function - (Figure 3A and B). In the case of the last
polymorphism, rs3783641, for the genotype mean value of vWF
concentration we observed no progression from Aa to aa
genotypes. This may suggest either a non-additive model of
association or simply reflect the fact that there were only 6 people
with the aa genotype in our study. Interestingly, 4 polymorphisms
(rs10483639, rs841, rs3783641, and rs8007267) were also associ-
ated with plasma MDA concentration, a systemic oxidative stress
marker (Figure 4A and B).
Figure 1. LD within GCH1 gene locus. (A) Extent of LD between polymorphisms at the GCH1 gene locus, based on HapMap Phase II data. Two
black triangles designate two haplotype blocks of tight LD. (B) Physical location and minor allele frequency of 5 genotyped polymorphisms from
GCH1 locus according to UCSC Genome Browser (Feb 2009 assembly). (C) LD analysis between 5 polymorphisms, genotyped in T2DM subjects from
the Polish population, forms two separate haplotype blocks. Data were analyzed and visualized with Haploview ver. 4.2. Haplotype blocks were
defined based on the solid spine of LD rule. Numeric values represent Lewontin’s D9 between pairs of polymorphisms.
doi:10.1371/journal.pone.0108587.g001
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Table 1. Clinical characteristics of the studied T2DM patients.
Clinical feature Value in 182 patients *
Female sex (%) 50
Age at examination (years) 56.5 [37–72]
Characteristics of T2DM
Use of oral antidiabetic drugs (%) 63.2 **
Use of insulin (%) 52.8 **
Any form of retinopathy (%) 39
Nephropathy (%) 16.5
Neuropathy (%) 34.1
Age at diagnosis (years) 47 [26–68]
Duration of diabetes (years) 9 [1–31]
Current blood glucose (mmol/L) 9.2 [4.3–34]
Hemoglobin A1c (%) 7.6 [5.1–14.2]
Peptide C (ng/mL) 3 [0.15–11.5]
Serum creatinine (mmol/L) 75.3 [47–386.4]
Renal dysfunction; serum creatinine.155 mmol/L (%) 5.0
ALAT (IU/L) 20 [8–90]
Risk factors for atherosclerosis
Hypertension (%) 88.5
Ever smoking status (%) 59.1
Current smoking status (%) 21.6
Overweight/Obesity (%) Overweight –29.7; Obese –59.9
BMI (kg/m2) 31.4 [21–56.4]
Total cholesterol (mmol/L) 5.1 [2.7–19.6]
LDL cholesterol (mmol/L) 2.9 [0.5–7.3]
HDL cholesterol (mmol/L) 1.1 [0.4–2.5]
Triglycerides (mmol/L) 1.9 [0.6–14.1]
Atherosclerosis and CAD
Ischaemic heart disease (%) 47.8
CCS classification (%) 0–50; 1–24.7; 2–17.6; 3–7.7
PTCA performed in the past (%) 11.5
Myocardial infarction in the past (%) 12.1
Presence of atherosclerotic plaque (%) 60.4
Medications
ACE inhibitors (%) 76.9
diuretics (%) 50
beta – blockers (%) 37
calcium blockers (%) 23.6
alpha – blockers (%) 7.7
nitrates (%) 14.8
aspirin (%) 43.4
statins (%) 49.7
Studied vascular endpoints
IMT (mm, average of 12 measurements) 0.84 [0.55–1.1]
IMT (mm, maximum of 12 measurements) 1 [0.7–1.5]
FMD (ratio to baseline at 5 minutes) 1.03 [1–1.24]
NMD (ratio to baseline at 5 minutes) 1.12 [1–1.31]
MDA (mmol/L) 3.32 [0.16–22.3]
vWF (% of normal population) 101.3 [37.5–144.1]
* Frequency of occurrence among patients for categorical variables or median [minimum; maximum] value for continuous variables.
** At the time of examination 42 T2DM patients use both insulin and oral hypoglycemic drugs, 54 use only insulin, 73 use only oral hypoglycemic drugs, 13 use neither
insulin nor oral hypoglycemic drugs (diet and physical exercises only).
doi:10.1371/journal.pone.0108587.t001
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Association of haplotypes with outcome variables
Association of each of the two described above haplotype blocks
with studied outcome variables was determined using omnibus
haplotype association tests with studied variables (Table 3).
Haplotype analysis showed that MDA concentration was
associated with both haplotype blocks while vWF concentration
was associated only with the first haplotype block. This is in line
with the analysis of associations of individual polymorphisms with
outcome variables. In addition, we observed that association of
both haplotype blocks with MDA concentration was less
significant than the ones of individual polymorphisms. However,
in case the of vWF concentration, the association of the first
haplotype block was more significant than that of any individual
polymorphism. There was no significant association between the
haplotype blocks and FMD values.
Clinical variables as potential confounders of GCH1
polymorphisms associations
In addition to single polymorphism analyses and haplotype
block analyses, we have also tested whether clinical covariates,
described in the Statistical Analysis paragraph of the Materials and
Methods section, changed the association between GCH1
polymorphisms and the outcome variables – FMD as well as
MDA and vWF concentrations. The only covariate that signifi-
cantly associated on its own with the outcome variables was
current smoking status. However, we also forced in kidney
dysfunction (defined as creatinine concentration above 155 ml/
L) and duration of diabetes into the multivariate models, as these
are known to particularly affect endothelial function in diabetes
(Table 4). The relationships between polymorphisms and outcome
variables were independent of the confounding variable of current
smoking status. Changes in beta coefficients of association for any
studied SNP were less than 10% upon addition of current smoking
as a covariate in the model. Thus, covariates did not confound this
relationship.
Discussion
In the present study we have found that polymorphisms in the
GCH1 gene, that can affect tetrahydrobiopterin synthesis, are
associated with markers of endothelial dysfunction and oxidative
Table 2. Association of individual GCH1 gene polymorphisms with outcome variables.
Outcome variable SNP P value
FMD (max) Rs10483639 0.056
Rs841 0.01
Rs3783641 0.09
Rs10137071 0.63
Rs8007267 0.47
NMD (max) Rs10483639 0.24
Rs841 0.25
Rs3783641 0.19
Rs10137071 0.29
Rs8007267 0.07
IMT (mean) Rs10483639 0.15
Rs841 0.22
Rs3783641 0.08
Rs10137071 0.28
Rs8007267 0.11
IMT (max) Rs10483639 0.21
Rs841 0.09
Rs3783641 0.06
Rs10137071 0.40
Rs8007267 0.13
MDA Rs10483639 0.012
Rs841 0.0015
Rs3783641 0.003
Rs10137071 0.51
Rs8007267 0.006
vWF Rs10483639 0.016
Rs841 0.03
Rs3783641 0.045
Rs10137071 0.75
Rs8007267 0.055
doi:10.1371/journal.pone.0108587.t002
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stress. This is important, as both endothelial dysfunction and
oxidative stress in T2DM patients are the major mechanisms for
the development of both micro- and macro-angiopathy. Further
studies are required to determine if the same association of
polymorphisms is true for patients with type 1 diabetes. Expanding
this study to include a group of healthy, non-diabetic control
subjects could also verify whether the described associations of
polymorphisms with endothelial dysfunction and oxidative stress
also remain significant during normoglycemia or are specific to
diabetic patients only.
Functional effects of polymorphisms located in the GCH1 gene
locus have been initially shown in relation to the role of BH4 in
catecholamine and serotonin synthesis [23]. Rare mutations in
GCH1 lead to hyperphenylalaninemia [24] or DOPA-responsive
dystonia [25]. However, the association of sequence differences in
this gene with NO biology have been quickly established. For
example, the GCH1 haplotype with population frequency of
15.4% has been linked to lower pain sensitivity due to decreased
NO production [15]. Although this association has not been
replicated [26], recent interest has focused on the relationship with
cardiovascular disease. Importantly, Lotsch et al. [27] demon-
strated that the pain-protective haplotype can be inferred by
genotyping just three polymorphisms, which we have included in
our analysis.
A number of studies have looked at cardiovascular disease in
relation to the GCH1 genetic variation. Zhang et al. [20] reported
that a GCH1 polymorphism in the 39-UTR is associated with
cardiovascular risk, due to decreased NO production and higher
Figure 3. Relationship between studied polymorphisms and plasma vWF concentration. Relationship to polymorphisms forming
haplotype block 1 (panel A) and haplotype block 2 (panel B) is demonstrated. Statistical significance of linear regression: * p,0.05.
doi:10.1371/journal.pone.0108587.g003
Figure 2. Relationship between rs841 polymorphism in the 3’-UTR of GCH1 gene and vascular function measured as endothelium
dependent FMD (panel A) and endothelium independent NMD) (panel B). AA indicates frequent homozygote, Aa - heterozygote, aa - rare
homozygote.
doi:10.1371/journal.pone.0108587.g002
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blood pressure in carriers of one of the alleles. Subsequently,
Doehring et al. [21] showed that this 39-UTR polymorphism is in
complete LD with the pain-modulating haplotype. Polymorphisms
rs1049255 and rs841 were independently associated with coronary
artery disease [28]. According to this study, epistatic interactions
with other polymorphisms of the NO biosynthesis pathway
contribute additionally to the risk of coronary artery disease.
The first direct link of genetic variation with BH4 levels was
described by Antoniades et al. [16]. They observed lower BH4
levels in carriers of the deleterious GCH1 haplotype, which results
in increased production of vascular superoxide and decreased
acetylcholine mediated vasodilation in saphenous vein fragments.
Considering this evidence and the role BH4 plays in diabetic
vascular disease, the importance of genetic variation of the GCH1
gene in T2DM patients is particularly interesting. Polymorphism
rs841, which forms a part of the first haplotype block, has been
implicated in macrovascular disease in the Chinese cohort of
T2DM patients [29]. In this earlier study, carriers of the
deleterious genotype were characterized by lower plasma NOx
concentrations and lower FMD but higher MDA level and IMT.
In the present project, we have studied 5 polymorphisms spread
throughout the gene, which has allowed us to look at variation in
the GCH1 gene. Careful examination of the structure of LD in the
Polish cohort of T2DM patients showed that these polymorphisms
belong to two separate haplotype blocks, in agreement with our
analysis of HapMap data. A previous study reported the existence
of various numbers of haplotype blocks in the GCH1 locus,
depending on the population studied [15]. Two earlier papers
suggested tight LD across the whole GCH1 locus [16,21].
However, Zhang and et al. [20], who performed a resequencing
Table 3. Association of two GCH1 gene haplotype blocks, formed by 5 studied polymorphisms with outcome variables.
Studied variable Haplotype block * P value for association
FMD max 1 0.27
2 0.72
NMD 1 0.6
2 0.16
IMT (average) 1 0.5
2 0.1
IMT (max) 1 0.44
2 0.16
MDA 1 0.0253
2 0.0145
vWF 1 0.00285
2 0.12
* Haplotype block 1 consists of the following SNPs: Rs10483639, Rs841, Rs3783641 (estimated haplotype frequencies: GAT 79.9%; CGA 15.4%; GAA 2%; CGT 2%.
Haplotype block 2 consists of the following SNPs: Rs10137071, Rs8007267 (estimated haplotype frequencies: AC 75.5%; AT 16.8%; GC 7.7%).
doi:10.1371/journal.pone.0108587.t003
Figure 4. Relationship between studied polymorphisms and plasma MDA concentration measured by mass-spec analysis.
Relationship to polymorphisms forming haplotype block 1 (panel A) and haplotype block 2 (panel B) is demonstrated. Statistical significance of linear
regression: * p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0108587.g004
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study, report two distinct haplotype blocks in subjects from Sub-
Saharan Africa and a lack of LD of the 39-end polymorphism with
other areas of the gene in subjects of European ancestry.
Therefore, our careful examination of the structure of LD in the
Polish population in the context of HapMap data is of great
interest.
We found that only one of the polymorphisms, rs841, was
associated with impaired endothelium dependent vascular dilata-
tion while no relationship was observed with non-endothelium
dependent responses. This is in agreement with previous reports of
the functional effects of this polymorphism on vascular function in
T2DM. Subsequently, we found that three polymorphisms, which
form the first haplotype block, were also associated with biomarker
Table 4. Models of association of GCH1 gene polymorphisms with outcome variables, accounting for current smoking, kidney
dysfunction* and diabetes duration covariates.
Outcome variable Model including single SNP Model including SNP and covariates Beta coefficient P value
FMD max rs841 20.018 0.01
rs841 20.017 0.015
Current smoking 20.011 0.2
Renal dysfunction 20.0009 0.17
Diabetes duration 20.0022 0.93
MDA rs10483639 1.216 0.01
rs10483639 1.042 0.03
Current smoking 20.84 0.15
Renal dysfunction 0.06 0.23
Diabetes duration 20.8 0.42
rs841 1.583 0.001
rs841 20.755 0.19
Current smoking 0.04 0.35
Renal dysfunction 21.341 0.44
Diabetes duration 1.431 0.005
rs3783641 1.457 0.003
rs3783641 1.298 0.01
Current smoking 20.931 0.10
Renal dysfunction 0.0412 0.35
Diabetes duration 21.068 0.50
rs8007267 1.337 0.006
rs8007267 1.136 0.024
Current smoking 20.862 0.14
Renal dysfunction 0.05 0.28
Diabetes duration 21.243 0.44
vWF rs10483639 26.453 0.016
rs10483639 25.706 0.033
Current smoking 24.99 0.12
Renal dysfunction 0.098 0.69
Diabetes duration 16.91 0.03
rs841 25.839 0.031
rs841 25.371 0.047
Current smoking 24.546 0.13
Renal dysfunction 20.069 0.78
Diabetes duration 15.47 0.065
rs3783641 25.445 0.045
rs3783641 24.728 0.081
Current smoking 24.486 0.15
Renal dysfunction 20.0389 0.87
Diabetes duration 16.8 0.03
* Renal dysfunction is defined as patients having creatinine concentration above 155 mmol/L.
doi:10.1371/journal.pone.0108587.t004
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plasma vWF concentration, which clearly confirms the functional
importance of the GCH1 gene variability in the regulation of
vascular function in T2DM.
The major mechanism through which the GCH1 gene could
affect endothelial function is eNOS uncoupling, which is directly
linked to oxidative stress. Four polymorphisms, three constituting
the first haplotype block and one from the second haplotype block,
are associated with MDA plasma concentration. Moreover, the
first haplotype block was even more strongly associated with this
variable than any of the analyzed SNPs. This finding suggests that
the first haplotype block may contain a non-genotyped polymor-
phism affecting MDA concentration. Therefore, this would be a
stronger association than any of the polymorphisms previously
genotyped by our group. An alternative explanation to this finding
could be an epigenetic interaction between studied polymorphisms
or other polymorphisms in haplotype block 1, modifying the
presence of CpG islands in this locus, thereby affecting methyl-
ation pattern and expression of GCH1. Such a possibility was
demonstrated at other loci [30]. In the case of vWF, association of
the first haplotype block with this variable was less significant than
with individual SNPs.
We also tested whether associations defined in this study could
have been confounded by clinical factors. The only clinical
variable associated with the outcome variables of MDA and vWF
concentrations (but not with FMD), was the current smoking
status. However, further statistical analysis has shown that the
association of SNPs with outcome variables was not confounded
by smoking, renal dysfunction, or diabetes duration. In summary,
GCH1 polymorphisms or haplotype blocks are associated with
FMD, malondialdehyde, and von Willebrand factor concentra-
tions, independently of other clinical characteristics in Polish
T2DM patients.
Interestingly, in our T2DM study group we did not observe an
association between GCH1 genetic variation and IMT, which has
been reported previously [29]. It is possible that our patients were
younger and their IMT was overall not substantially increased
(mean IMT below 0.9 mm). This could have implicated that we
studied a population of T2DM patients at early stage of the
development of atherosclerotic disease in whom an increase of
IMT not yet developed. However, as discussed above, our data
show that the functional polymorphisms, which may affect NO
production, can also influence intermediate phenotypes of
endothelial dysfunction and imbalanced redox homeostasis [31].
We cannot exclude an alternative explanation that slight
interindividual differences in IMT, measured in fraction of
millimeters are harder to associate with effects of polymorphism.
Such a relationship would be easier to find in a larger population.
Macrovascular complications are responsible for mortality
excess and lower quality of life in T2DM patients. Their
occurrence may be accelerated and exacerbated by a deficiency
in NO production [32]. While NO donors (such as nitrates) are
widely used in some clinical situations, their protective efficacy in
coronary artery disease has been questioned in numerous clinical
trials [33]. Therefore, they do not constitute a first line treatment
any longer. Correction of BH4 deficiency might be a better
therapeutic option correcting not only NO deficiency but
oxidative stress as well. For example, it has been postulated that
in carriers of susceptibility GCH1 gene polymorphisms with
elevated MDA, BH4 may be oxidized to BH2 and uncouple NO
synthase, which leads to further production of reactive oxygen
species by eNOS, rather than NO itself [34–36]. The findings of
our study together with published evidence of the functional
importance in GCH1 gene variation may in future form a basis for
diagnostic screening tests to stratify the risk of early development
of macrovascular complications in newly diagnosed T2DM
patients. This also presents potential therapeutic implications that
will need to be clinically tested. An interesting question would be
whether supplementation of BH4 might improve the clinical
course of T2DM macrovascular complications in relation to
stratification based on GCH1 gene polymorphisms. Stratification
of patients’ therapy according to their genotype is an important
aspect of personalized medicine, which becomes even more
possible with the advent of new, genome-wide laboratory tools.
Apart from the correction of NO availability, another important
strategy for preventing complications in diabetic patients could be
to reverse endothelial progenitor cell dysfunction [37]. GCH1was
demonstrated to effectively reverse such dysfunction and promote
re-endothelization, which may be important for wound healing
[37,38]. A group of patients who are particularly prone to
complications due to endothelial dysfunction, and might therefore
especially benefit from genotype-based BH4 correction, are
patients with kidney-pancreas transplantation [39–41].
In summary, the results of our study indicate that functional
polymorphisms of the GTP cyclohydrolase I gene, which directly
affect tetrahydrobiopterin synthesis, are associated with endothe-
lial dysfunction and oxidative stress in T2DM patients.
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